Iovance Shares Continue Descent Despite Strategic Distribution Deal
Published on 09/26/2025 at 04:36 | Redaktion boerse-global.de
Iovance Biotherapeutics’ stock remains entrenched in a pronounced downward trajectory, with shares declining an additional 3.3% in the latest trading session. This persistent selling pressure underscores a significant challenge for the biotechnology firm: even concrete operational developments are failing to counteract the prevailing negative sentiment among investors.
In a notable operational move, Iovance has announced a strategic partnership aimed at broadening patient access to its key therapy, Amtagvi. The company is collaborating with McKesson’s specialty pharmacy, InspiroGene, to establish a new distribution channel. This initiative is designed to streamline the process for treatment centers, allowing them to procure Amtagvi through their preferred suppliers while simultaneously reducing administrative burdens for healthcare providers. A central goal of the collaboration is to... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
